Oncocyte Corp Stock Gross Profit

OCX Stock

USD 2.44 0.09 3.56%

OncoCyte Corp fundamentals help investors to digest information that contributes to OncoCyte Corp's financial success or failures. It also enables traders to predict the movement of OncoCyte Stock. The fundamental analysis module provides a way to measure OncoCyte Corp's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to OncoCyte Corp stock.

	Last Reported	Projected for Next Year
Gross Profit	413 K	433.6 K
Gross Profit Margin	0.27	0.29

Gross Profit is likely to rise to about 433.6 K in 2024. Gross Profit Margin is likely to rise to 0.29 in 2024.

This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

OncoCyte Corp Company Gross Profit Analysis

OncoCyte Corp's Gross Profit is the most basic measure of business operational efficiency. It is simply the difference between sales revenue and the cost associated with making a product or providing a service. It is calculated before deducting administrative expenses, taxes, and interest payments.

Gross Profit

Revenue

-

Cost of Revenue

More About Gross Profit | All Equity Analysis

Current OncoCyte Corp Gross Profit

188 K

Most of OncoCyte Corp's fundamental indicators, such as Gross Profit, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, OncoCyte Corp is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.

OncoCyte Gross Profit Driver Correlations

Understanding the fundamental principles of building solid financial models for OncoCyte Corp is extremely important. It helps to project a fair market value of OncoCyte Stock properly, considering its historical fundamentals such as Gross Profit. Since OncoCyte Corp's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of OncoCyte Corp's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of OncoCyte Corp's interrelated accounts and indicators.

	Total Assets	Total Stockholder Equity	Net Debt	Retained Earnings	Accounts Payable	Short Term Investments	Total Liab	Total Current Assets	Short Term Debt	Intangible Assets	Common Stock	Property Plant Equipment	Net Tangible Assets	Long Term Debt	Short Long Term Debt	Current Deferred Revenue	Long Term Debt Total	Net Invested Capital	Net Working Capital	Capital Stock	Long Term Investments	Net Receivables
Total Assets		0.95	-0.8	-0.75	0.98	-0.55	0.98	0.88	-0.04	0.93	0.8	0.82	-0.71	0.72	0.65	0.55	0.68	0.92	0.73	0.86	-0.78	0.82
Total Stockholder Equity	0.95		-0.82	-0.68	0.91	-0.59	0.88	0.91	-0.1	0.84	0.74	0.79	-0.5	0.79	0.72	0.59	0.75	0.98	0.76	0.76	-0.63	0.69
Net Debt	-0.8	-0.82		0.54	-0.85	0.62	-0.74	-0.96	0.44	-0.74	-0.6	-0.56	0.4	-0.6	-0.41	-0.62	-0.6	-0.75	-0.85	-0.58	0.61	-0.68
Retained Earnings	-0.75	-0.68	0.54		-0.76	0.76	-0.76	-0.58	0.26	-0.88	-0.99	-0.97	0.58	-0.73	-0.7	-0.73	-0.75	-0.67	-0.3	-0.96	0.89	-0.64
Accounts Payable	0.98	0.91	-0.85	-0.76		-0.56	0.98	0.9	-0.14	0.93	0.8	0.8	-0.73	0.68	0.57	0.57	0.64	0.86	0.73	0.86	-0.83	0.85
Short Term Investments	-0.55	-0.59	0.62	0.76	-0.56		-0.5	-0.56	0.47	-0.61	-0.77	-0.72	0.14	-0.75	-0.77	-0.93	-0.82	-0.57	-0.29	-0.64	0.52	-0.37
Total Liab	0.98	0.88	-0.74	-0.76	0.98	-0.5		0.82	0.0	0.94	0.79	0.8	-0.82	0.64	0.57	0.5	0.61	0.84	0.67	0.87	-0.84	0.87
Total Current Assets	0.88	0.91	-0.96	-0.58	0.9	-0.56	0.82		-0.24	0.8	0.65	0.64	-0.48	0.65	0.47	0.57	0.63	0.88	0.9	0.65	-0.65	0.76
Short Term Debt	-0.04	-0.1	0.44	0.26	-0.14	0.47	0.0	-0.24		-0.1	-0.24	-0.16	-0.18	-0.2	-0.15	-0.53	-0.25	0.03	-0.03	-0.14	0.17	-0.05
Intangible Assets	0.93	0.84	-0.74	-0.88	0.93	-0.61	0.94	0.8	-0.1		0.91	0.9	-0.8	0.64	0.57	0.6	0.64	0.83	0.6	0.92	-0.93	0.79
Common Stock	0.8	0.74	-0.6	-0.99	0.8	-0.77	0.79	0.65	-0.24	0.91		0.99	-0.6	0.75	0.72	0.74	0.77	0.74	0.37	0.96	-0.89	0.66
Property Plant Equipment	0.82	0.79	-0.56	-0.97	0.8	-0.72	0.8	0.64	-0.16	0.9	0.99		-0.59	0.77	0.77	0.7	0.78	0.79	0.36	0.95	-0.85	0.62
Net Tangible Assets	-0.71	-0.5	0.4	0.58	-0.73	0.14	-0.82	-0.48	-0.18	-0.8	-0.6	-0.59		-0.18	-0.18	-0.17	-0.18	-0.51	-0.34	-0.67	0.82	-0.7
Long Term Debt	0.72	0.79	-0.6	-0.73	0.68	-0.75	0.64	0.65	-0.2	0.64	0.75	0.77	-0.18		0.84	0.72	0.98	0.76	0.55	0.75	-0.51	0.48
Short Long Term Debt	0.65	0.72	-0.41	-0.7	0.57	-0.77	0.57	0.47	-0.15	0.57	0.72	0.77	-0.18	0.84		0.77	0.83	0.71	0.22	0.68	-0.37	0.37
Current Deferred Revenue	0.55	0.59	-0.62	-0.73	0.57	-0.93	0.5	0.57	-0.53	0.6	0.74	0.7	-0.17	0.72	0.77		0.78	0.57	0.29	0.61	-0.5	0.36
Long Term Debt Total	0.68	0.75	-0.6	-0.75	0.64	-0.82	0.61	0.63	-0.25	0.64	0.77	0.78	-0.18	0.98	0.83	0.78		0.74	0.5	0.73	-0.53	0.44
Net Invested Capital	0.92	0.98	-0.75	-0.67	0.86	-0.57	0.84	0.88	0.03	0.83	0.74	0.79	-0.51	0.76	0.71	0.57	0.74		0.74	0.73	-0.62	0.66
Net Working Capital	0.73	0.76	-0.85	-0.3	0.73	-0.29	0.67	0.9	-0.03	0.6	0.37	0.36	-0.34	0.55	0.22	0.29	0.5	0.74		0.42	-0.45	0.64
Capital Stock	0.86	0.76	-0.58	-0.96	0.86	-0.64	0.87	0.65	-0.14	0.92	0.96	0.95	-0.67	0.75	0.68	0.61	0.73	0.73	0.42		-0.91	0.75
Long Term Investments	-0.78	-0.63	0.61	0.89	-0.83	0.52	-0.84	-0.65	0.17	-0.93	-0.89	-0.85	0.82	-0.51	-0.37	-0.5	-0.53	-0.62	-0.45	-0.91		-0.75
Net Receivables	0.82	0.69	-0.68	-0.64	0.85	-0.37	0.87	0.76	-0.05	0.79	0.66	0.62	-0.7	0.48	0.37	0.36	0.44	0.66	0.64	0.75	-0.75

Click cells to compare fundamentals

Gross Profit varies significantly from one sector to another and tells an investor how much money a business would have made if it didn't have to pay any overhead expenses such as salary, taxes, or rent.

Competition

Predict OncoCyte Corp

Gross Profit Over Time

According to the company disclosure, OncoCyte Corp reported 188 K of gross profit. This is 99.99% lower than that of the Biotechnology sector and 99.98% lower than that of the Health Care industry. The gross profit for all United States stocks is 100.0% higher than that of the company.

OncoCyte Gross Profit Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses OncoCyte Corp's direct or indirect competition against its Gross Profit to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of OncoCyte Corp could also be used in its relative valuation, which is a method of valuing OncoCyte Corp by comparing valuation metrics of similar companies.

OncoCyte Corp is currently under evaluation in gross profit category among its peers.

OncoCyte Corp ESG Sustainability

Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, OncoCyte Corp's sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to OncoCyte Corp's managers, analysts, and investors.

Environmental

Governance

Social

OncoCyte Fundamentals

	Return On Equity	-1.65
	Return On Asset	-0.19
	Operating Margin	(55.43) %
	Current Valuation	43.22 M
	Shares Outstanding	16.84 M
	Shares Owned By Insiders	15.95 %
	Shares Owned By Institutions	50.58 %
	Number Of Shares Shorted	194.19 K
	Price To Earning	(12.20) X
	Price To Book	4.39 X
	Price To Sales	60.07 X
	Revenue	1.5 M
	Gross Profit	188 K
	EBITDA	(23.12 M)
	Net Income	(27.78 M)
	Cash And Equivalents	45.41 M
	Cash Per Share	0.38 X
	Total Debt	2.87 M
	Debt To Equity	0.05 %
	Current Ratio	3.49 X
	Book Value Per Share	0.71 X
	Cash Flow From Operations	(23.32 M)
	Short Ratio	3.80 X
	Earnings Per Share	(4.44) X
	Target Price	4.25
	Number Of Employees	43
	Beta	1.0
	Market Capitalization	42.59 M
	Total Asset	74.89 M
	Retained Earnings	(289.88 M)
	Working Capital	3.5 M
	Current Asset	15.28 M
	Current Liabilities	3.97 M
	Net Asset	74.89 M

About OncoCyte Corp Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze OncoCyte Corp's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of OncoCyte Corp using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of OncoCyte Corp based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Please read more on our fundamental analysis page.

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

ESRT	Empire State Realty
C	Citigroup
C	Citigroup

Additional Tools for OncoCyte Stock Analysis

When running OncoCyte Corp's price analysis, check to measure OncoCyte Corp's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy OncoCyte Corp is operating at the current time. Most of OncoCyte Corp's value examination focuses on studying past and present price action to predict the probability of OncoCyte Corp's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move OncoCyte Corp's price. Additionally, you may evaluate how the addition of OncoCyte Corp to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC